nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—testicular cancer	0.389	1	CtDrD
Gefitinib—STK10—testicular cancer	0.375	1	CbGaD
Gefitinib—ABCG2—Dactinomycin—testicular cancer	0.0161	0.122	CbGbCtD
Gefitinib—ABCG2—Carboplatin—testicular cancer	0.0108	0.0821	CbGbCtD
Gefitinib—CYP3A5—Ifosfamide—testicular cancer	0.0105	0.08	CbGbCtD
Gefitinib—ABCG2—Cisplatin—testicular cancer	0.00925	0.0702	CbGbCtD
Gefitinib—ABCG2—Etoposide—testicular cancer	0.00909	0.069	CbGbCtD
Gefitinib—CYP2C19—Ifosfamide—testicular cancer	0.0085	0.0645	CbGbCtD
Gefitinib—CYP2C9—Ifosfamide—testicular cancer	0.00707	0.0536	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—testicular cancer	0.0062	0.047	CbGbCtD
Gefitinib—ABCG2—Methotrexate—testicular cancer	0.00601	0.0456	CbGbCtD
Gefitinib—ABCB1—Dactinomycin—testicular cancer	0.00581	0.0441	CbGbCtD
Gefitinib—CYP3A5—Etoposide—testicular cancer	0.00504	0.0382	CbGbCtD
Gefitinib—ALB—Methotrexate—testicular cancer	0.00414	0.0314	CbGbCtD
Gefitinib—CYP3A4—Ifosfamide—testicular cancer	0.00411	0.0312	CbGbCtD
Gefitinib—ABCB1—Vinblastine—testicular cancer	0.00364	0.0276	CbGbCtD
Gefitinib—CYP2C9—Cisplatin—testicular cancer	0.00344	0.0261	CbGbCtD
Gefitinib—CYP2D6—Vinblastine—testicular cancer	0.00343	0.026	CbGbCtD
Gefitinib—ABCB1—Cisplatin—testicular cancer	0.00334	0.0253	CbGbCtD
Gefitinib—ABCB1—Etoposide—testicular cancer	0.00328	0.0249	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—testicular cancer	0.00224	0.017	CbGbCtD
Gefitinib—CYP3A4—Vinblastine—testicular cancer	0.00218	0.0165	CbGbCtD
Gefitinib—ABCB1—Methotrexate—testicular cancer	0.00217	0.0164	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—testicular cancer	0.00211	0.016	CbGbCtD
Gefitinib—CYP3A4—Etoposide—testicular cancer	0.00196	0.0149	CbGbCtD
Gefitinib—Erlotinib—STK10—testicular cancer	0.00137	0.44	CrCbGaD
Gefitinib—CYP3A4—Doxorubicin—testicular cancer	0.00134	0.0102	CbGbCtD
Gefitinib—HIPK4—gonad—testicular cancer	0.00108	0.0431	CbGeAlD
Gefitinib—Vandetanib—STK10—testicular cancer	0.000899	0.29	CrCbGaD
Gefitinib—ERBB3—embryo—testicular cancer	0.000854	0.0342	CbGeAlD
Gefitinib—EPHA6—gonad—testicular cancer	0.00085	0.0341	CbGeAlD
Gefitinib—Bosutinib—STK10—testicular cancer	0.000841	0.271	CrCbGaD
Gefitinib—CSNK1E—seminal vesicle—testicular cancer	0.000832	0.0333	CbGeAlD
Gefitinib—IRAK4—seminal vesicle—testicular cancer	0.000819	0.0328	CbGeAlD
Gefitinib—SBK1—testis—testicular cancer	0.000784	0.0314	CbGeAlD
Gefitinib—HIPK4—testis—testicular cancer	0.000775	0.0311	CbGeAlD
Gefitinib—CHEK2—female gonad—testicular cancer	0.00077	0.0309	CbGeAlD
Gefitinib—MKNK2—seminal vesicle—testicular cancer	0.000763	0.0306	CbGeAlD
Gefitinib—CHEK2—testis—testicular cancer	0.000683	0.0274	CbGeAlD
Gefitinib—EPHA6—testis—testicular cancer	0.000613	0.0246	CbGeAlD
Gefitinib—SBK1—lymph node—testicular cancer	0.000568	0.0228	CbGeAlD
Gefitinib—MAP3K19—testis—testicular cancer	0.000557	0.0223	CbGeAlD
Gefitinib—MAP2K5—seminal vesicle—testicular cancer	0.000554	0.0222	CbGeAlD
Gefitinib—MKNK2—gonad—testicular cancer	0.000551	0.0221	CbGeAlD
Gefitinib—MKNK1—gonad—testicular cancer	0.000544	0.0218	CbGeAlD
Gefitinib—EGFR—female gonad—testicular cancer	0.000508	0.0204	CbGeAlD
Gefitinib—CHEK2—lymph node—testicular cancer	0.000495	0.0198	CbGeAlD
Gefitinib—CSNK1E—female gonad—testicular cancer	0.000488	0.0196	CbGeAlD
Gefitinib—IRAK4—female gonad—testicular cancer	0.000481	0.0193	CbGeAlD
Gefitinib—ERBB3—female gonad—testicular cancer	0.000471	0.0189	CbGeAlD
Gefitinib—EGFR—testis—testicular cancer	0.00045	0.018	CbGeAlD
Gefitinib—STK10—gonad—testicular cancer	0.000448	0.018	CbGeAlD
Gefitinib—MKNK2—female gonad—testicular cancer	0.000448	0.018	CbGeAlD
Gefitinib—IRAK1—female gonad—testicular cancer	0.000448	0.018	CbGeAlD
Gefitinib—MKNK1—female gonad—testicular cancer	0.000442	0.0177	CbGeAlD
Gefitinib—CSNK1E—testis—testicular cancer	0.000433	0.0174	CbGeAlD
Gefitinib—IRAK4—testis—testicular cancer	0.000426	0.0171	CbGeAlD
Gefitinib—ERBB3—testis—testicular cancer	0.000418	0.0167	CbGeAlD
Gefitinib—MKNK2—testis—testicular cancer	0.000397	0.0159	CbGeAlD
Gefitinib—IRAK1—testis—testicular cancer	0.000397	0.0159	CbGeAlD
Gefitinib—MKNK1—testis—testicular cancer	0.000392	0.0157	CbGeAlD
Gefitinib—STK10—female gonad—testicular cancer	0.000364	0.0146	CbGeAlD
Gefitinib—CHEK2—Vindesine—Vinblastine—testicular cancer	0.000343	0.2	CbGdCrCtD
Gefitinib—EGFR—lymph node—testicular cancer	0.000327	0.0131	CbGeAlD
Gefitinib—MAP2K5—female gonad—testicular cancer	0.000325	0.013	CbGeAlD
Gefitinib—STK10—testis—testicular cancer	0.000323	0.0129	CbGeAlD
Gefitinib—ERBB3—Podofilox—Etoposide—testicular cancer	0.00032	0.187	CbGdCrCtD
Gefitinib—CSNK1E—lymph node—testicular cancer	0.000314	0.0126	CbGeAlD
Gefitinib—IRAK4—lymph node—testicular cancer	0.000309	0.0124	CbGeAlD
Gefitinib—ERBB3—lymph node—testicular cancer	0.000303	0.0121	CbGeAlD
Gefitinib—MAP2K5—testis—testicular cancer	0.000289	0.0116	CbGeAlD
Gefitinib—MKNK2—lymph node—testicular cancer	0.000288	0.0115	CbGeAlD
Gefitinib—IRAK1—lymph node—testicular cancer	0.000288	0.0115	CbGeAlD
Gefitinib—MKNK1—lymph node—testicular cancer	0.000284	0.0114	CbGeAlD
Gefitinib—ABCG2—seminal vesicle—testicular cancer	0.00027	0.0108	CbGeAlD
Gefitinib—STK10—lymph node—testicular cancer	0.000234	0.00939	CbGeAlD
Gefitinib—CHEK2—Vinorelbine—Vinblastine—testicular cancer	0.000216	0.126	CbGdCrCtD
Gefitinib—CHEK2—Teniposide—Etoposide—testicular cancer	0.000216	0.126	CbGdCrCtD
Gefitinib—CHEK2—Podofilox—Etoposide—testicular cancer	0.000216	0.126	CbGdCrCtD
Gefitinib—MAP2K5—lymph node—testicular cancer	0.000209	0.00838	CbGeAlD
Gefitinib—ALB—testis—testicular cancer	0.000205	0.00823	CbGeAlD
Gefitinib—CHEK2—Vincristine—Vinblastine—testicular cancer	0.000185	0.108	CbGdCrCtD
Gefitinib—ORM1—lymph node—testicular cancer	0.00017	0.0068	CbGeAlD
Gefitinib—ABCG2—female gonad—testicular cancer	0.000158	0.00634	CbGeAlD
Gefitinib—CYP1A1—female gonad—testicular cancer	0.00015	0.00602	CbGeAlD
Gefitinib—ALB—lymph node—testicular cancer	0.000149	0.00597	CbGeAlD
Gefitinib—CYP3A5—female gonad—testicular cancer	0.000147	0.00589	CbGeAlD
Gefitinib—ABCB1—embryo—testicular cancer	0.000142	0.00567	CbGeAlD
Gefitinib—ABCG2—testis—testicular cancer	0.00014	0.00563	CbGeAlD
Gefitinib—ABCB1—seminal vesicle—testicular cancer	0.000133	0.00533	CbGeAlD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—testicular cancer	0.000113	0.0658	CbGdCrCtD
Gefitinib—CYP2D6—female gonad—testicular cancer	0.000109	0.00435	CbGeAlD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—testicular cancer	0.000104	0.0609	CbGdCrCtD
Gefitinib—ABCG2—lymph node—testicular cancer	0.000102	0.00408	CbGeAlD
Gefitinib—CYP1A1—lymph node—testicular cancer	9.66e-05	0.00387	CbGeAlD
Gefitinib—CYP2D6—testis—testicular cancer	9.62e-05	0.00386	CbGeAlD
Gefitinib—ABCB1—gonad—testicular cancer	9.6e-05	0.00385	CbGeAlD
Gefitinib—ABCB1—female gonad—testicular cancer	7.81e-05	0.00313	CbGeAlD
Gefitinib—ABCB1—testis—testicular cancer	6.92e-05	0.00277	CbGeAlD
Gefitinib—Malaise—Etoposide—testicular cancer	6.71e-05	0.00114	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—testicular cancer	6.7e-05	0.00114	CcSEcCtD
Gefitinib—Decreased appetite—Ifosfamide—testicular cancer	6.68e-05	0.00114	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—testicular cancer	6.66e-05	0.00113	CcSEcCtD
Gefitinib—ERBB3—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	6.64e-05	0.00425	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Ifosfamide—testicular cancer	6.63e-05	0.00113	CcSEcCtD
Gefitinib—Abdominal pain—Dactinomycin—testicular cancer	6.63e-05	0.00113	CcSEcCtD
Gefitinib—Body temperature increased—Dactinomycin—testicular cancer	6.63e-05	0.00113	CcSEcCtD
Gefitinib—Fatigue—Ifosfamide—testicular cancer	6.63e-05	0.00113	CcSEcCtD
Gefitinib—Hypersensitivity—Bleomycin—testicular cancer	6.63e-05	0.00113	CcSEcCtD
Gefitinib—Infection—Cisplatin—testicular cancer	6.58e-05	0.00112	CcSEcCtD
Gefitinib—Constipation—Ifosfamide—testicular cancer	6.57e-05	0.00112	CcSEcCtD
Gefitinib—Pain—Ifosfamide—testicular cancer	6.57e-05	0.00112	CcSEcCtD
Gefitinib—EGFR—PI3K/AKT activation—KITLG—testicular cancer	6.54e-05	0.00419	CbGpPWpGaD
Gefitinib—Nervous system disorder—Cisplatin—testicular cancer	6.5e-05	0.0011	CcSEcCtD
Gefitinib—Cough—Etoposide—testicular cancer	6.49e-05	0.0011	CcSEcCtD
Gefitinib—Thrombocytopenia—Cisplatin—testicular cancer	6.49e-05	0.0011	CcSEcCtD
Gefitinib—EGFR—GAB1 signalosome—KITLG—testicular cancer	6.48e-05	0.00416	CbGpPWpGaD
Gefitinib—Asthenia—Bleomycin—testicular cancer	6.45e-05	0.0011	CcSEcCtD
Gefitinib—Dehydration—Epirubicin—testicular cancer	6.44e-05	0.00109	CcSEcCtD
Gefitinib—Skin disorder—Cisplatin—testicular cancer	6.44e-05	0.00109	CcSEcCtD
Gefitinib—EGFR—B Cell Activation—BCL10—testicular cancer	6.4e-05	0.0041	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signaling of activated FGFR—FGFR3—testicular cancer	6.39e-05	0.0041	CbGpPWpGaD
Gefitinib—Pruritus—Bleomycin—testicular cancer	6.36e-05	0.00108	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—testicular cancer	6.35e-05	0.00108	CcSEcCtD
Gefitinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	6.34e-05	0.00406	CbGpPWpGaD
Gefitinib—Nausea—Vinblastine—testicular cancer	6.32e-05	0.00107	CcSEcCtD
Gefitinib—Anorexia—Cisplatin—testicular cancer	6.32e-05	0.00107	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—testicular cancer	6.3e-05	0.00107	CcSEcCtD
Gefitinib—ERBB3—Signaling by ERBB4—FGFR3—testicular cancer	6.29e-05	0.00403	CbGpPWpGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	6.29e-05	0.00107	CcSEcCtD
Gefitinib—Gastrointestinal pain—Ifosfamide—testicular cancer	6.28e-05	0.00107	CcSEcCtD
Gefitinib—MKNK1—Signaling Pathways—INSL3—testicular cancer	6.28e-05	0.00403	CbGpPWpGaD
Gefitinib—Pancreatitis—Methotrexate—testicular cancer	6.27e-05	0.00107	CcSEcCtD
Gefitinib—CSNK1E—Cell Cycle—MAD1L1—testicular cancer	6.25e-05	0.004	CbGpPWpGaD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—testicular cancer	6.23e-05	0.00106	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—testicular cancer	6.23e-05	0.00106	CcSEcCtD
Gefitinib—Hypotension—Cisplatin—testicular cancer	6.19e-05	0.00105	CcSEcCtD
Gefitinib—Hypersensitivity—Dactinomycin—testicular cancer	6.18e-05	0.00105	CcSEcCtD
Gefitinib—ERBB3—Signaling by SCF-KIT—KIT—testicular cancer	6.13e-05	0.00393	CbGpPWpGaD
Gefitinib—Alanine aminotransferase increased—Epirubicin—testicular cancer	6.11e-05	0.00104	CcSEcCtD
Gefitinib—Urticaria—Ifosfamide—testicular cancer	6.11e-05	0.00104	CcSEcCtD
Gefitinib—Body temperature increased—Ifosfamide—testicular cancer	6.08e-05	0.00103	CcSEcCtD
Gefitinib—Abdominal pain—Ifosfamide—testicular cancer	6.08e-05	0.00103	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—BCL10—testicular cancer	6.06e-05	0.00388	CbGpPWpGaD
Gefitinib—Infection—Etoposide—testicular cancer	6.03e-05	0.00102	CcSEcCtD
Gefitinib—Asthenia—Dactinomycin—testicular cancer	6.02e-05	0.00102	CcSEcCtD
Gefitinib—ERBB3—Downstream signal transduction—FGFR3—testicular cancer	6.01e-05	0.00385	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by FGFR—FGFR3—testicular cancer	5.98e-05	0.00383	CbGpPWpGaD
Gefitinib—ABCG2—Transmembrane transport of small molecules—SLC2A6—testicular cancer	5.96e-05	0.00382	CbGpPWpGaD
Gefitinib—Dehydration—Doxorubicin—testicular cancer	5.96e-05	0.00101	CcSEcCtD
Gefitinib—ERBB3—Signaling by ERBB2—FGFR3—testicular cancer	5.95e-05	0.00381	CbGpPWpGaD
Gefitinib—Thrombocytopenia—Etoposide—testicular cancer	5.94e-05	0.00101	CcSEcCtD
Gefitinib—ERBB3—DAP12 signaling—FGFR3—testicular cancer	5.92e-05	0.00379	CbGpPWpGaD
Gefitinib—Dyspnoea—Cisplatin—testicular cancer	5.91e-05	0.001	CcSEcCtD
Gefitinib—Skin disorder—Etoposide—testicular cancer	5.9e-05	0.001	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—testicular cancer	5.87e-05	0.000998	CcSEcCtD
Gefitinib—ERBB3—Downstream signaling of activated FGFR—KIT—testicular cancer	5.87e-05	0.00376	CbGpPWpGaD
Gefitinib—Pancreatitis—Epirubicin—testicular cancer	5.87e-05	0.000997	CcSEcCtD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	5.84e-05	0.00374	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	5.83e-05	0.00374	CbGpPWpGaD
Gefitinib—Hypokalaemia—Doxorubicin—testicular cancer	5.83e-05	0.000991	CcSEcCtD
Gefitinib—Anorexia—Etoposide—testicular cancer	5.79e-05	0.000983	CcSEcCtD
Gefitinib—ERBB3—Signaling by ERBB4—KIT—testicular cancer	5.78e-05	0.0037	CbGpPWpGaD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	5.77e-05	0.00098	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	5.77e-05	0.00098	CcSEcCtD
Gefitinib—Decreased appetite—Cisplatin—testicular cancer	5.76e-05	0.000979	CcSEcCtD
Gefitinib—Diarrhoea—Dactinomycin—testicular cancer	5.74e-05	0.000975	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—testicular cancer	5.73e-05	0.000974	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cisplatin—testicular cancer	5.72e-05	0.000972	CcSEcCtD
Gefitinib—Vomiting—Bleomycin—testicular cancer	5.72e-05	0.000972	CcSEcCtD
Gefitinib—Infestation—Methotrexate—testicular cancer	5.7e-05	0.000969	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—testicular cancer	5.7e-05	0.000969	CcSEcCtD
Gefitinib—EGFR—LPA receptor mediated events—MMP2—testicular cancer	5.69e-05	0.00365	CbGpPWpGaD
Gefitinib—Hypotension—Etoposide—testicular cancer	5.67e-05	0.000964	CcSEcCtD
Gefitinib—Rash—Bleomycin—testicular cancer	5.67e-05	0.000964	CcSEcCtD
Gefitinib—Pain—Cisplatin—testicular cancer	5.67e-05	0.000963	CcSEcCtD
Gefitinib—Dermatitis—Bleomycin—testicular cancer	5.66e-05	0.000963	CcSEcCtD
Gefitinib—Hypersensitivity—Ifosfamide—testicular cancer	5.66e-05	0.000962	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—testicular cancer	5.65e-05	0.000961	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—testicular cancer	5.65e-05	0.00096	CcSEcCtD
Gefitinib—ERBB3—Signaling by FGFR in disease—FGFR3—testicular cancer	5.57e-05	0.00357	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 interactions—FGFR3—testicular cancer	5.57e-05	0.00357	CbGpPWpGaD
Gefitinib—ERBB3—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	5.57e-05	0.00357	CbGpPWpGaD
Gefitinib—Stomatitis—Methotrexate—testicular cancer	5.56e-05	0.000944	CcSEcCtD
Gefitinib—EGFR—AGE/RAGE pathway—MMP2—testicular cancer	5.55e-05	0.00356	CbGpPWpGaD
Gefitinib—Conjunctivitis—Methotrexate—testicular cancer	5.54e-05	0.000942	CcSEcCtD
Gefitinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	5.52e-05	0.00354	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR—FGFR3—testicular cancer	5.52e-05	0.00354	CbGpPWpGaD
Gefitinib—ERBB3—Downstream signal transduction—KIT—testicular cancer	5.52e-05	0.00354	CbGpPWpGaD
Gefitinib—Asthenia—Ifosfamide—testicular cancer	5.51e-05	0.000937	CcSEcCtD
Gefitinib—ERBB3—Signaling by FGFR—KIT—testicular cancer	5.49e-05	0.00352	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR in Cancer—FGFR3—testicular cancer	5.47e-05	0.00351	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by ERBB2—KIT—testicular cancer	5.46e-05	0.0035	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by PDGF—FGFR3—testicular cancer	5.45e-05	0.00349	CbGpPWpGaD
Gefitinib—Pruritus—Ifosfamide—testicular cancer	5.44e-05	0.000924	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—testicular cancer	5.44e-05	0.000924	CcSEcCtD
Gefitinib—ERBB3—DAP12 signaling—KIT—testicular cancer	5.44e-05	0.00348	CbGpPWpGaD
Gefitinib—Pancreatitis—Doxorubicin—testicular cancer	5.43e-05	0.000922	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—testicular cancer	5.41e-05	0.00092	CcSEcCtD
Gefitinib—Dyspnoea—Etoposide—testicular cancer	5.41e-05	0.00092	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—testicular cancer	5.39e-05	0.000916	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—testicular cancer	5.38e-05	0.000914	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—testicular cancer	5.37e-05	0.000912	CcSEcCtD
Gefitinib—ERBB3—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	5.36e-05	0.00343	CbGpPWpGaD
Gefitinib—Nausea—Bleomycin—testicular cancer	5.34e-05	0.000908	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—testicular cancer	5.33e-05	0.000907	CcSEcCtD
Gefitinib—Infestation—Epirubicin—testicular cancer	5.33e-05	0.000907	CcSEcCtD
Gefitinib—Vomiting—Dactinomycin—testicular cancer	5.33e-05	0.000906	CcSEcCtD
Gefitinib—MAP2K5—Signaling by NGF—KITLG—testicular cancer	5.3e-05	0.00339	CbGpPWpGaD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—testicular cancer	5.29e-05	0.000899	CcSEcCtD
Gefitinib—Rash—Dactinomycin—testicular cancer	5.29e-05	0.000899	CcSEcCtD
Gefitinib—Decreased appetite—Etoposide—testicular cancer	5.28e-05	0.000897	CcSEcCtD
Gefitinib—Diarrhoea—Ifosfamide—testicular cancer	5.26e-05	0.000894	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Etoposide—testicular cancer	5.24e-05	0.000891	CcSEcCtD
Gefitinib—Body temperature increased—Cisplatin—testicular cancer	5.24e-05	0.00089	CcSEcCtD
Gefitinib—Fatigue—Etoposide—testicular cancer	5.23e-05	0.000889	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—testicular cancer	5.2e-05	0.000884	CcSEcCtD
Gefitinib—Pain—Etoposide—testicular cancer	5.19e-05	0.000882	CcSEcCtD
Gefitinib—Constipation—Etoposide—testicular cancer	5.19e-05	0.000882	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—testicular cancer	5.19e-05	0.000881	CcSEcCtD
Gefitinib—ERBB3—B Cell Activation—FGFR3—testicular cancer	5.15e-05	0.0033	CbGpPWpGaD
Gefitinib—Haemoglobin—Methotrexate—testicular cancer	5.14e-05	0.000874	CcSEcCtD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—STK11—testicular cancer	5.12e-05	0.00328	CbGpPWpGaD
Gefitinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	5.12e-05	0.00328	CbGpPWpGaD
Gefitinib—Hepatitis—Methotrexate—testicular cancer	5.12e-05	0.00087	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—testicular cancer	5.12e-05	0.00087	CcSEcCtD
Gefitinib—ERBB3—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	5.11e-05	0.00328	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by FGFR in disease—KIT—testicular cancer	5.11e-05	0.00328	CbGpPWpGaD
Gefitinib—ERBB3—DAP12 interactions—KIT—testicular cancer	5.11e-05	0.00328	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—KITLG—testicular cancer	5.1e-05	0.00327	CbGpPWpGaD
Gefitinib—Haematuria—Epirubicin—testicular cancer	5.09e-05	0.000864	CcSEcCtD
Gefitinib—CHEK2—Cell Cycle—H2AFZ—testicular cancer	5.08e-05	0.00326	CbGpPWpGaD
Gefitinib—EGFR—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	5.07e-05	0.00325	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by EGFR—KIT—testicular cancer	5.07e-05	0.00325	CbGpPWpGaD
Gefitinib—Urinary tract disorder—Methotrexate—testicular cancer	5.05e-05	0.000859	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—testicular cancer	5.05e-05	0.000858	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—testicular cancer	5.03e-05	0.000855	CcSEcCtD
Gefitinib—ERBB3—Signaling by EGFR in Cancer—KIT—testicular cancer	5.02e-05	0.00322	CbGpPWpGaD
Gefitinib—ABCB1—lymph node—testicular cancer	5.02e-05	0.00201	CbGeAlD
Gefitinib—Urethral disorder—Methotrexate—testicular cancer	5.02e-05	0.000853	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—testicular cancer	5.01e-05	0.000851	CcSEcCtD
Gefitinib—EGFR—Signaling by SCF-KIT—KITLG—testicular cancer	5e-05	0.00321	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by PDGF—KIT—testicular cancer	5e-05	0.0032	CbGpPWpGaD
Gefitinib—Nausea—Dactinomycin—testicular cancer	4.98e-05	0.000847	CcSEcCtD
Gefitinib—EGFR—PI-3K cascade—FGFR3—testicular cancer	4.98e-05	0.00319	CbGpPWpGaD
Gefitinib—Pneumonia—Doxorubicin—testicular cancer	4.96e-05	0.000844	CcSEcCtD
Gefitinib—Gastrointestinal pain—Etoposide—testicular cancer	4.96e-05	0.000844	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—testicular cancer	4.94e-05	0.000839	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—testicular cancer	4.94e-05	0.000839	CcSEcCtD
Gefitinib—ERBB3—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	4.93e-05	0.00316	CbGpPWpGaD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	4.89e-05	0.000832	CcSEcCtD
Gefitinib—CSNK1E—Signaling Pathways—INSL3—testicular cancer	4.89e-05	0.00313	CbGpPWpGaD
Gefitinib—Vomiting—Ifosfamide—testicular cancer	4.89e-05	0.00083	CcSEcCtD
Gefitinib—Hypersensitivity—Cisplatin—testicular cancer	4.88e-05	0.00083	CcSEcCtD
Gefitinib—CSNK1E—Cell Cycle, Mitotic—H2AFZ—testicular cancer	4.87e-05	0.00312	CbGpPWpGaD
Gefitinib—EGFR—PI3K/AKT activation—FGFR3—testicular cancer	4.86e-05	0.00311	CbGpPWpGaD
Gefitinib—Rash—Ifosfamide—testicular cancer	4.85e-05	0.000824	CcSEcCtD
Gefitinib—Dermatitis—Ifosfamide—testicular cancer	4.84e-05	0.000823	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—testicular cancer	4.84e-05	0.000822	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—BCL10—testicular cancer	4.83e-05	0.00309	CbGpPWpGaD
Gefitinib—Urticaria—Etoposide—testicular cancer	4.82e-05	0.00082	CcSEcCtD
Gefitinib—EGFR—GAB1 signalosome—FGFR3—testicular cancer	4.82e-05	0.00309	CbGpPWpGaD
Gefitinib—Haemoglobin—Epirubicin—testicular cancer	4.81e-05	0.000818	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—testicular cancer	4.81e-05	0.000818	CcSEcCtD
Gefitinib—Abdominal pain—Etoposide—testicular cancer	4.8e-05	0.000816	CcSEcCtD
Gefitinib—Body temperature increased—Etoposide—testicular cancer	4.8e-05	0.000816	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—testicular cancer	4.8e-05	0.000815	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—testicular cancer	4.79e-05	0.000814	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—testicular cancer	4.79e-05	0.000814	CcSEcCtD
Gefitinib—EGFR—Downstream signaling of activated FGFR—KITLG—testicular cancer	4.79e-05	0.00307	CbGpPWpGaD
Gefitinib—Eye disorder—Methotrexate—testicular cancer	4.78e-05	0.000813	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—testicular cancer	4.75e-05	0.000808	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—testicular cancer	4.75e-05	0.000807	CcSEcCtD
Gefitinib—ERBB3—B Cell Activation—KIT—testicular cancer	4.73e-05	0.00303	CbGpPWpGaD
Gefitinib—Urinary tract disorder—Epirubicin—testicular cancer	4.73e-05	0.000804	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—testicular cancer	4.72e-05	0.000802	CcSEcCtD
Gefitinib—EGFR—Signaling by ERBB4—KITLG—testicular cancer	4.71e-05	0.00302	CbGpPWpGaD
Gefitinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	4.71e-05	0.00302	CbGpPWpGaD
Gefitinib—Haematuria—Doxorubicin—testicular cancer	4.71e-05	0.0008	CcSEcCtD
Gefitinib—MAP2K5—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	4.7e-05	0.00301	CbGpPWpGaD
Gefitinib—Urethral disorder—Epirubicin—testicular cancer	4.69e-05	0.000798	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—testicular cancer	4.67e-05	0.000793	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—testicular cancer	4.66e-05	0.000791	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—testicular cancer	4.64e-05	0.000789	CcSEcCtD
Gefitinib—ERBB3—Adaptive Immune System—BCL10—testicular cancer	4.64e-05	0.00297	CbGpPWpGaD
Gefitinib—Mediastinal disorder—Methotrexate—testicular cancer	4.61e-05	0.000784	CcSEcCtD
Gefitinib—EGFR—PI-3K cascade—KIT—testicular cancer	4.57e-05	0.00293	CbGpPWpGaD
Gefitinib—Nausea—Ifosfamide—testicular cancer	4.56e-05	0.000776	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—testicular cancer	4.53e-05	0.00077	CcSEcCtD
Gefitinib—ERBB3—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	4.53e-05	0.0029	CbGpPWpGaD
Gefitinib—Erythema multiforme—Epirubicin—testicular cancer	4.53e-05	0.00077	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—testicular cancer	4.52e-05	0.000769	CcSEcCtD
Gefitinib—EGFR—Downstream signal transduction—KITLG—testicular cancer	4.5e-05	0.00288	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR—KITLG—testicular cancer	4.48e-05	0.00287	CbGpPWpGaD
Gefitinib—Eye disorder—Epirubicin—testicular cancer	4.48e-05	0.000761	CcSEcCtD
Gefitinib—Hypersensitivity—Etoposide—testicular cancer	4.47e-05	0.00076	CcSEcCtD
Gefitinib—EGFR—PI3K/AKT activation—KIT—testicular cancer	4.46e-05	0.00286	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—KITLG—testicular cancer	4.46e-05	0.00286	CbGpPWpGaD
Gefitinib—Malnutrition—Methotrexate—testicular cancer	4.45e-05	0.000757	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—testicular cancer	4.45e-05	0.000757	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—testicular cancer	4.44e-05	0.000755	CcSEcCtD
Gefitinib—EGFR—DAP12 signaling—KITLG—testicular cancer	4.43e-05	0.00284	CbGpPWpGaD
Gefitinib—Haemorrhage—Doxorubicin—testicular cancer	4.43e-05	0.000753	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—testicular cancer	4.43e-05	0.000753	CcSEcCtD
Gefitinib—EGFR—GAB1 signalosome—KIT—testicular cancer	4.42e-05	0.00284	CbGpPWpGaD
Gefitinib—Urinary tract disorder—Doxorubicin—testicular cancer	4.38e-05	0.000744	CcSEcCtD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	4.37e-05	0.0028	CbGpPWpGaD
Gefitinib—Oedema peripheral—Doxorubicin—testicular cancer	4.37e-05	0.000742	CcSEcCtD
Gefitinib—Asthenia—Etoposide—testicular cancer	4.35e-05	0.00074	CcSEcCtD
Gefitinib—CSNK1E—Cell Cycle—H2AFZ—testicular cancer	4.35e-05	0.00279	CbGpPWpGaD
Gefitinib—EPHA6—Axon guidance—MMP2—testicular cancer	4.35e-05	0.00279	CbGpPWpGaD
Gefitinib—Angiopathy—Epirubicin—testicular cancer	4.35e-05	0.000738	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—testicular cancer	4.34e-05	0.000738	CcSEcCtD
Gefitinib—EGFR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	4.32e-05	0.00277	CbGpPWpGaD
Gefitinib—Mediastinal disorder—Epirubicin—testicular cancer	4.32e-05	0.000734	CcSEcCtD
Gefitinib—Pruritus—Etoposide—testicular cancer	4.29e-05	0.00073	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—testicular cancer	4.28e-05	0.000727	CcSEcCtD
Gefitinib—IRAK1—Signaling by NGF—KITLG—testicular cancer	4.25e-05	0.00272	CbGpPWpGaD
Gefitinib—CYP3A5—Biological oxidations—HPGDS—testicular cancer	4.25e-05	0.00272	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	4.24e-05	0.00272	CbGpPWpGaD
Gefitinib—Alopecia—Epirubicin—testicular cancer	4.23e-05	0.000719	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—testicular cancer	4.21e-05	0.000716	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—testicular cancer	4.19e-05	0.000712	CcSEcCtD
Gefitinib—Rash—Cisplatin—testicular cancer	4.18e-05	0.00071	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—testicular cancer	4.17e-05	0.000709	CcSEcCtD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	4.17e-05	0.00267	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—KITLG—testicular cancer	4.17e-05	0.00267	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—KITLG—testicular cancer	4.17e-05	0.00267	CbGpPWpGaD
Gefitinib—Malnutrition—Epirubicin—testicular cancer	4.17e-05	0.000709	CcSEcCtD
Gefitinib—Diarrhoea—Etoposide—testicular cancer	4.15e-05	0.000706	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—testicular cancer	4.14e-05	0.000704	CcSEcCtD
Gefitinib—EGFR—Signaling by EGFR—KITLG—testicular cancer	4.13e-05	0.00265	CbGpPWpGaD
Gefitinib—Anaemia—Methotrexate—testicular cancer	4.12e-05	0.0007	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—testicular cancer	4.11e-05	0.000699	CcSEcCtD
Gefitinib—EGFR—Signaling by EGFR in Cancer—KITLG—testicular cancer	4.1e-05	0.00263	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—KITLG—testicular cancer	4.08e-05	0.00261	CbGpPWpGaD
Gefitinib—Angiopathy—Doxorubicin—testicular cancer	4.02e-05	0.000683	CcSEcCtD
Gefitinib—IRAK1—Innate Immune System—BCL10—testicular cancer	4.02e-05	0.00258	CbGpPWpGaD
Gefitinib—Malaise—Methotrexate—testicular cancer	4.02e-05	0.000683	CcSEcCtD
Gefitinib—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—testicular cancer	4.01e-05	0.00257	CbGpPWpGaD
Gefitinib—CYP1A1—Biological oxidations—HPGDS—testicular cancer	4.01e-05	0.00257	CbGpPWpGaD
Gefitinib—Mediastinal disorder—Doxorubicin—testicular cancer	3.99e-05	0.000679	CcSEcCtD
Gefitinib—Arrhythmia—Doxorubicin—testicular cancer	3.96e-05	0.000673	CcSEcCtD
Gefitinib—MAP2K5—Signaling by NGF—FGFR3—testicular cancer	3.94e-05	0.00252	CbGpPWpGaD
Gefitinib—Nausea—Cisplatin—testicular cancer	3.94e-05	0.000669	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—testicular cancer	3.92e-05	0.000666	CcSEcCtD
Gefitinib—Cough—Methotrexate—testicular cancer	3.89e-05	0.000661	CcSEcCtD
Gefitinib—MAP2K5—Signaling Pathways—INSL3—testicular cancer	3.86e-05	0.00248	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—KITLG—testicular cancer	3.86e-05	0.00247	CbGpPWpGaD
Gefitinib—Vomiting—Etoposide—testicular cancer	3.86e-05	0.000656	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—testicular cancer	3.86e-05	0.000656	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—testicular cancer	3.85e-05	0.000655	CcSEcCtD
Gefitinib—Rash—Etoposide—testicular cancer	3.83e-05	0.00065	CcSEcCtD
Gefitinib—Dermatitis—Etoposide—testicular cancer	3.82e-05	0.00065	CcSEcCtD
Gefitinib—ERBB3—Signaling by NGF—FGFR3—testicular cancer	3.79e-05	0.00243	CbGpPWpGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	3.77e-05	0.00064	CcSEcCtD
Gefitinib—Malaise—Epirubicin—testicular cancer	3.76e-05	0.000639	CcSEcCtD
Gefitinib—ERBB3—Signaling Pathways—INSL3—testicular cancer	3.72e-05	0.00239	CbGpPWpGaD
Gefitinib—EGFR—Signaling by SCF-KIT—FGFR3—testicular cancer	3.72e-05	0.00238	CbGpPWpGaD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	3.69e-05	0.00237	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.68e-05	0.00236	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—KITLG—testicular cancer	3.65e-05	0.00234	CbGpPWpGaD
Gefitinib—Cough—Epirubicin—testicular cancer	3.64e-05	0.000618	CcSEcCtD
Gefitinib—MAP2K5—Signaling by NGF—KIT—testicular cancer	3.61e-05	0.00232	CbGpPWpGaD
Gefitinib—Infection—Methotrexate—testicular cancer	3.61e-05	0.000614	CcSEcCtD
Gefitinib—Nausea—Etoposide—testicular cancer	3.61e-05	0.000613	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—testicular cancer	3.57e-05	0.000606	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—testicular cancer	3.57e-05	0.000606	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—testicular cancer	3.56e-05	0.000605	CcSEcCtD
Gefitinib—EGFR—Downstream signaling of activated FGFR—FGFR3—testicular cancer	3.56e-05	0.00228	CbGpPWpGaD
Gefitinib—EGFR—Regulation of Actin Cytoskeleton—FGFR3—testicular cancer	3.56e-05	0.00228	CbGpPWpGaD
Gefitinib—Skin disorder—Methotrexate—testicular cancer	3.53e-05	0.0006	CcSEcCtD
Gefitinib—IRAK4—Immune System—BCL10—testicular cancer	3.53e-05	0.00226	CbGpPWpGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	3.52e-05	0.000599	CcSEcCtD
Gefitinib—EGFR—Signaling by GPCR—INSL3—testicular cancer	3.51e-05	0.00225	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—FGFR3—testicular cancer	3.5e-05	0.00224	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—KIT—testicular cancer	3.48e-05	0.00223	CbGpPWpGaD
Gefitinib—Malaise—Doxorubicin—testicular cancer	3.48e-05	0.000591	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—testicular cancer	3.47e-05	0.00059	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—testicular cancer	3.47e-05	0.000589	CcSEcCtD
Gefitinib—EGFR—Signaling by SCF-KIT—KIT—testicular cancer	3.41e-05	0.00219	CbGpPWpGaD
Gefitinib—Hypotension—Methotrexate—testicular cancer	3.4e-05	0.000577	CcSEcCtD
Gefitinib—Infection—Epirubicin—testicular cancer	3.38e-05	0.000574	CcSEcCtD
Gefitinib—Cough—Doxorubicin—testicular cancer	3.37e-05	0.000572	CcSEcCtD
Gefitinib—Shock—Epirubicin—testicular cancer	3.35e-05	0.000569	CcSEcCtD
Gefitinib—EGFR—Downstream signal transduction—FGFR3—testicular cancer	3.34e-05	0.00214	CbGpPWpGaD
Gefitinib—Nervous system disorder—Epirubicin—testicular cancer	3.34e-05	0.000567	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—testicular cancer	3.33e-05	0.000566	CcSEcCtD
Gefitinib—EGFR—Signaling by FGFR—FGFR3—testicular cancer	3.33e-05	0.00213	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—FGFR3—testicular cancer	3.31e-05	0.00212	CbGpPWpGaD
Gefitinib—Skin disorder—Epirubicin—testicular cancer	3.3e-05	0.000562	CcSEcCtD
Gefitinib—EGFR—DAP12 signaling—FGFR3—testicular cancer	3.3e-05	0.00211	CbGpPWpGaD
Gefitinib—CYP2C19—Biological oxidations—HPGDS—testicular cancer	3.28e-05	0.0021	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling of activated FGFR—KIT—testicular cancer	3.27e-05	0.00209	CbGpPWpGaD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	3.26e-05	0.000554	CcSEcCtD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	3.25e-05	0.00208	CbGpPWpGaD
Gefitinib—Anorexia—Epirubicin—testicular cancer	3.24e-05	0.000551	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—testicular cancer	3.24e-05	0.000551	CcSEcCtD
Gefitinib—ABCB1—Transmembrane transport of small molecules—SLC2A6—testicular cancer	3.22e-05	0.00207	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB4—KIT—testicular cancer	3.22e-05	0.00206	CbGpPWpGaD
Gefitinib—Dry mouth—Doxorubicin—testicular cancer	3.21e-05	0.000546	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—testicular cancer	3.18e-05	0.00054	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—testicular cancer	3.16e-05	0.000537	CcSEcCtD
Gefitinib—IRAK1—Signaling by NGF—FGFR3—testicular cancer	3.16e-05	0.00202	CbGpPWpGaD
Gefitinib—Gastrointestinal disorder—Methotrexate—testicular cancer	3.14e-05	0.000533	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—testicular cancer	3.13e-05	0.000533	CcSEcCtD
Gefitinib—Infection—Doxorubicin—testicular cancer	3.13e-05	0.000532	CcSEcCtD
Gefitinib—Pain—Methotrexate—testicular cancer	3.11e-05	0.000528	CcSEcCtD
Gefitinib—EPHA6—Developmental Biology—MMP2—testicular cancer	3.1e-05	0.00199	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	3.1e-05	0.00199	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—FGFR3—testicular cancer	3.1e-05	0.00199	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—FGFR3—testicular cancer	3.1e-05	0.00199	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—INSL3—testicular cancer	3.1e-05	0.00199	CbGpPWpGaD
Gefitinib—Shock—Doxorubicin—testicular cancer	3.1e-05	0.000526	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—testicular cancer	3.09e-05	0.000525	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—testicular cancer	3.08e-05	0.000524	CcSEcCtD
Gefitinib—EGFR—Signaling by EGFR—FGFR3—testicular cancer	3.07e-05	0.00197	CbGpPWpGaD
Gefitinib—EGFR—Downstream signal transduction—KIT—testicular cancer	3.07e-05	0.00197	CbGpPWpGaD
Gefitinib—Skin disorder—Doxorubicin—testicular cancer	3.06e-05	0.00052	CcSEcCtD
Gefitinib—EGFR—Signaling by FGFR—KIT—testicular cancer	3.06e-05	0.00196	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR in Cancer—FGFR3—testicular cancer	3.05e-05	0.00195	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—MMP2—testicular cancer	3.04e-05	0.00195	CbGpPWpGaD
Gefitinib—EGFR—Signaling by ERBB2—KIT—testicular cancer	3.04e-05	0.00195	CbGpPWpGaD
Gefitinib—Dyspnoea—Epirubicin—testicular cancer	3.03e-05	0.000516	CcSEcCtD
Gefitinib—EGFR—Signaling by PDGF—FGFR3—testicular cancer	3.03e-05	0.00194	CbGpPWpGaD
Gefitinib—EGFR—DAP12 signaling—KIT—testicular cancer	3.03e-05	0.00194	CbGpPWpGaD
Gefitinib—CYP2D6—Biological oxidations—HPGDS—testicular cancer	3.02e-05	0.00194	CbGpPWpGaD
Gefitinib—Anorexia—Doxorubicin—testicular cancer	3e-05	0.00051	CcSEcCtD
Gefitinib—CYP2C9—Biological oxidations—HPGDS—testicular cancer	2.99e-05	0.00192	CbGpPWpGaD
Gefitinib—EGFR—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	2.98e-05	0.00191	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Methotrexate—testicular cancer	2.97e-05	0.000505	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—testicular cancer	2.96e-05	0.000503	CcSEcCtD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	2.95e-05	0.00189	CbGpPWpGaD
Gefitinib—Hypotension—Doxorubicin—testicular cancer	2.94e-05	0.0005	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—testicular cancer	2.94e-05	0.000499	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—testicular cancer	2.93e-05	0.000499	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—KITLG—testicular cancer	2.91e-05	0.00187	CbGpPWpGaD
Gefitinib—Pain—Epirubicin—testicular cancer	2.91e-05	0.000495	CcSEcCtD
Gefitinib—Constipation—Epirubicin—testicular cancer	2.91e-05	0.000495	CcSEcCtD
Gefitinib—IRAK1—Signaling by NGF—KIT—testicular cancer	2.9e-05	0.00186	CbGpPWpGaD
Gefitinib—Urticaria—Methotrexate—testicular cancer	2.89e-05	0.000491	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—testicular cancer	2.87e-05	0.000488	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—testicular cancer	2.87e-05	0.000488	CcSEcCtD
Gefitinib—MKNK1—Disease—H2AFZ—testicular cancer	2.87e-05	0.00184	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—FGFR3—testicular cancer	2.87e-05	0.00184	CbGpPWpGaD
Gefitinib—EGFR—Signaling by FGFR in disease—KIT—testicular cancer	2.85e-05	0.00182	CbGpPWpGaD
Gefitinib—EGFR—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	2.85e-05	0.00182	CbGpPWpGaD
Gefitinib—EGFR—DAP12 interactions—KIT—testicular cancer	2.85e-05	0.00182	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KITLG—testicular cancer	2.84e-05	0.00182	CbGpPWpGaD
Gefitinib—EGFR—Signaling by EGFR—KIT—testicular cancer	2.82e-05	0.00181	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—BCL10—testicular cancer	2.81e-05	0.0018	CbGpPWpGaD
Gefitinib—Dyspnoea—Doxorubicin—testicular cancer	2.81e-05	0.000477	CcSEcCtD
Gefitinib—EGFR—Signaling by EGFR in Cancer—KIT—testicular cancer	2.8e-05	0.00179	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KITLG—testicular cancer	2.8e-05	0.00179	CbGpPWpGaD
Gefitinib—EGFR—Signaling by PDGF—KIT—testicular cancer	2.78e-05	0.00178	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Epirubicin—testicular cancer	2.78e-05	0.000473	CcSEcCtD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	2.75e-05	0.00176	CbGpPWpGaD
Gefitinib—Decreased appetite—Doxorubicin—testicular cancer	2.74e-05	0.000465	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—testicular cancer	2.72e-05	0.000462	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—testicular cancer	2.71e-05	0.000461	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—FGFR3—testicular cancer	2.71e-05	0.00174	CbGpPWpGaD
Gefitinib—Urticaria—Epirubicin—testicular cancer	2.7e-05	0.000459	CcSEcCtD
Gefitinib—Pain—Doxorubicin—testicular cancer	2.69e-05	0.000458	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—testicular cancer	2.69e-05	0.000458	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—testicular cancer	2.69e-05	0.000457	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—testicular cancer	2.69e-05	0.000457	CcSEcCtD
Gefitinib—EGFR—Innate Immune System—BCL10—testicular cancer	2.69e-05	0.00172	CbGpPWpGaD
Gefitinib—Hypersensitivity—Methotrexate—testicular cancer	2.68e-05	0.000455	CcSEcCtD
Gefitinib—MKNK1—Disease—KITLG—testicular cancer	2.64e-05	0.00169	CbGpPWpGaD
Gefitinib—EGFR—B Cell Activation—KIT—testicular cancer	2.63e-05	0.00169	CbGpPWpGaD
Gefitinib—Asthenia—Methotrexate—testicular cancer	2.61e-05	0.000443	CcSEcCtD
Gefitinib—EGFR—Adaptive Immune System—BCL10—testicular cancer	2.58e-05	0.00165	CbGpPWpGaD
Gefitinib—Gastrointestinal pain—Doxorubicin—testicular cancer	2.57e-05	0.000438	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—testicular cancer	2.57e-05	0.000437	CcSEcCtD
Gefitinib—EGFR—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	2.52e-05	0.00162	CbGpPWpGaD
Gefitinib—Hypersensitivity—Epirubicin—testicular cancer	2.51e-05	0.000426	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—testicular cancer	2.5e-05	0.000425	CcSEcCtD
Gefitinib—IRAK4—Innate Immune System—KIT—testicular cancer	2.49e-05	0.0016	CbGpPWpGaD
Gefitinib—Abdominal pain—Doxorubicin—testicular cancer	2.49e-05	0.000423	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—testicular cancer	2.49e-05	0.000423	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—testicular cancer	2.49e-05	0.000423	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—testicular cancer	2.44e-05	0.000415	CcSEcCtD
Gefitinib—IRAK1—Innate Immune System—KITLG—testicular cancer	2.42e-05	0.00155	CbGpPWpGaD
Gefitinib—Pruritus—Epirubicin—testicular cancer	2.41e-05	0.000409	CcSEcCtD
Gefitinib—IRAK1—Immune System—BCL10—testicular cancer	2.34e-05	0.0015	CbGpPWpGaD
Gefitinib—Diarrhoea—Epirubicin—testicular cancer	2.33e-05	0.000396	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—testicular cancer	2.32e-05	0.000394	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—testicular cancer	2.31e-05	0.000393	CcSEcCtD
Gefitinib—Rash—Methotrexate—testicular cancer	2.29e-05	0.00039	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—testicular cancer	2.29e-05	0.000389	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—testicular cancer	2.26e-05	0.000384	CcSEcCtD
Gefitinib—CSNK1E—Disease—H2AFZ—testicular cancer	2.23e-05	0.00143	CbGpPWpGaD
Gefitinib—Pruritus—Doxorubicin—testicular cancer	2.23e-05	0.000379	CcSEcCtD
Gefitinib—ERBB3—Innate Immune System—FGFR3—testicular cancer	2.16e-05	0.00139	CbGpPWpGaD
Gefitinib—Vomiting—Epirubicin—testicular cancer	2.16e-05	0.000368	CcSEcCtD
Gefitinib—Nausea—Methotrexate—testicular cancer	2.16e-05	0.000367	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—testicular cancer	2.15e-05	0.000366	CcSEcCtD
Gefitinib—Rash—Epirubicin—testicular cancer	2.15e-05	0.000365	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—testicular cancer	2.14e-05	0.000364	CcSEcCtD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	2.14e-05	0.00137	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KITLG—testicular cancer	2.13e-05	0.00136	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—FGFR3—testicular cancer	2.11e-05	0.00135	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—FGFR3—testicular cancer	2.08e-05	0.00133	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—INSL3—testicular cancer	2.07e-05	0.00133	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KITLG—testicular cancer	2.05e-05	0.00132	CbGpPWpGaD
Gefitinib—Nausea—Epirubicin—testicular cancer	2.02e-05	0.000343	CcSEcCtD
Gefitinib—MKNK1—Signaling Pathways—H2AFZ—testicular cancer	2.01e-05	0.00129	CbGpPWpGaD
Gefitinib—Vomiting—Doxorubicin—testicular cancer	2e-05	0.00034	CcSEcCtD
Gefitinib—MKNK1—Signaling Pathways—STK11—testicular cancer	2e-05	0.00128	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—KIT—testicular cancer	1.99e-05	0.00127	CbGpPWpGaD
Gefitinib—Rash—Doxorubicin—testicular cancer	1.99e-05	0.000337	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—testicular cancer	1.98e-05	0.000337	CcSEcCtD
Gefitinib—CYP3A4—Biological oxidations—HPGDS—testicular cancer	1.97e-05	0.00127	CbGpPWpGaD
Gefitinib—MKNK1—Disease—FGFR3—testicular cancer	1.96e-05	0.00126	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—KIT—testicular cancer	1.94e-05	0.00124	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KIT—testicular cancer	1.91e-05	0.00122	CbGpPWpGaD
Gefitinib—Nausea—Doxorubicin—testicular cancer	1.87e-05	0.000318	CcSEcCtD
Gefitinib—MKNK1—Signaling Pathways—KITLG—testicular cancer	1.85e-05	0.00119	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KIT—testicular cancer	1.8e-05	0.00116	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—FGFR3—testicular cancer	1.8e-05	0.00115	CbGpPWpGaD
Gefitinib—ERBB3—Disease—H2AFZ—testicular cancer	1.7e-05	0.00109	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KITLG—testicular cancer	1.7e-05	0.00109	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KIT—testicular cancer	1.65e-05	0.00106	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KITLG—testicular cancer	1.62e-05	0.00104	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—FGFR3—testicular cancer	1.58e-05	0.00101	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KITLG—testicular cancer	1.57e-05	0.001	CbGpPWpGaD
Gefitinib—EGFR—Immune System—BCL10—testicular cancer	1.57e-05	0.001	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—H2AFZ—testicular cancer	1.56e-05	0.001	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KITLG—testicular cancer	1.56e-05	0.000998	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—STK11—testicular cancer	1.56e-05	0.000997	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP2—testicular cancer	1.56e-05	0.000997	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.54e-05	0.000987	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—FGFR3—testicular cancer	1.53e-05	0.000979	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KIT—testicular cancer	1.45e-05	0.00093	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KITLG—testicular cancer	1.44e-05	0.000922	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KITLG—testicular cancer	1.41e-05	0.000905	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.4e-05	0.0009	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KIT—testicular cancer	1.4e-05	0.000899	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—FGFR3—testicular cancer	1.38e-05	0.000881	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KIT—testicular cancer	1.26e-05	0.000809	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.26e-05	0.000808	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—FGFR3—testicular cancer	1.26e-05	0.000808	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—H2AFZ—testicular cancer	1.24e-05	0.000792	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—STK11—testicular cancer	1.23e-05	0.000788	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—FGFR3—testicular cancer	1.2e-05	0.000772	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—H2AFZ—testicular cancer	1.19e-05	0.000764	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—STK11—testicular cancer	1.18e-05	0.000759	CbGpPWpGaD
Gefitinib—ERBB3—Disease—FGFR3—testicular cancer	1.16e-05	0.000746	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KIT—testicular cancer	1.16e-05	0.000742	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—FGFR3—testicular cancer	1.16e-05	0.000741	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.15e-05	0.000737	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KITLG—testicular cancer	1.14e-05	0.000729	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP2—testicular cancer	1.11e-05	0.000711	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KIT—testicular cancer	1.11e-05	0.000709	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KITLG—testicular cancer	1.1e-05	0.000703	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—FGFR3—testicular cancer	1.07e-05	0.000685	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KIT—testicular cancer	1.07e-05	0.000685	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KIT—testicular cancer	1.06e-05	0.000681	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—FGFR3—testicular cancer	1.05e-05	0.000672	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—HPGDS—testicular cancer	1.01e-05	0.00065	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—H2AFZ—testicular cancer	9.92e-06	0.000636	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—STK11—testicular cancer	9.87e-06	0.000632	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KIT—testicular cancer	9.82e-06	0.000629	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KIT—testicular cancer	9.63e-06	0.000617	CbGpPWpGaD
Gefitinib—EGFR—Disease—H2AFZ—testicular cancer	9.47e-06	0.000607	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KITLG—testicular cancer	9.44e-06	0.000605	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KITLG—testicular cancer	9.13e-06	0.000585	CbGpPWpGaD
Gefitinib—EGFR—Disease—KITLG—testicular cancer	8.72e-06	0.000559	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—FGFR3—testicular cancer	8.45e-06	0.000542	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—FGFR3—testicular cancer	8.15e-06	0.000522	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KIT—testicular cancer	7.76e-06	0.000497	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KIT—testicular cancer	7.48e-06	0.000479	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—STK11—testicular cancer	7.37e-06	0.000472	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—HPGDS—testicular cancer	7.26e-06	0.000465	CbGpPWpGaD
Gefitinib—EGFR—Immune System—FGFR3—testicular cancer	7.02e-06	0.00045	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—HPGDS—testicular cancer	6.86e-06	0.00044	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—FGFR3—testicular cancer	6.78e-06	0.000435	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—H2AFZ—testicular cancer	6.63e-06	0.000425	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—STK11—testicular cancer	6.6e-06	0.000423	CbGpPWpGaD
Gefitinib—EGFR—Disease—FGFR3—testicular cancer	6.48e-06	0.000415	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KIT—testicular cancer	6.44e-06	0.000413	CbGpPWpGaD
Gefitinib—ALB—Metabolism—HPGDS—testicular cancer	6.26e-06	0.000401	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KIT—testicular cancer	6.23e-06	0.000399	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KITLG—testicular cancer	6.1e-06	0.000391	CbGpPWpGaD
Gefitinib—EGFR—Disease—KIT—testicular cancer	5.95e-06	0.000381	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—HPGDS—testicular cancer	5.62e-06	0.00036	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—HPGDS—testicular cancer	5.48e-06	0.000351	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—STK11—testicular cancer	5.28e-06	0.000338	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—HPGDS—testicular cancer	5.16e-06	0.000331	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—HPGDS—testicular cancer	5.12e-06	0.000328	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—STK11—testicular cancer	4.99e-06	0.00032	CbGpPWpGaD
Gefitinib—ALB—Metabolism—STK11—testicular cancer	4.54e-06	0.000291	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—FGFR3—testicular cancer	4.54e-06	0.000291	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIT—testicular cancer	4.17e-06	0.000267	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—STK11—testicular cancer	4.08e-06	0.000261	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—STK11—testicular cancer	3.98e-06	0.000255	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—STK11—testicular cancer	3.75e-06	0.00024	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—STK11—testicular cancer	3.72e-06	0.000238	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—HPGDS—testicular cancer	3.38e-06	0.000216	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—STK11—testicular cancer	2.45e-06	0.000157	CbGpPWpGaD
